LENALIDOMIDA SANDOZ 7,5 mg Romunija - romunščina - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

lenalidomida sandoz 7,5 mg

synthon hispania, s.l. - spania - lenalidomidum - caps. - 7,5mg - imunosupresoare alte imunosupresoare

Ultomiris Evropska unija - romunščina - EMA (European Medicines Agency)

ultomiris

alexion europe sas - ravulizumab - hemoglobinurie, paroxismal - imunosupresoare selective - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.

LENALIDOMIDA GLENMARK 10 mg Romunija - romunščina - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

lenalidomida glenmark 10 mg

synthon hispania, s.l. - spania - lenalidomidum - caps. - 10mg - imunosupresoare alte imunosupresoare

LENALIDOMIDA GLENMARK 15 mg Romunija - romunščina - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

lenalidomida glenmark 15 mg

synthon hispania, s.l. - spania - lenalidomidum - caps. - 15mg - imunosupresoare alte imunosupresoare

LENALIDOMIDA GLENMARK 25 mg Romunija - romunščina - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

lenalidomida glenmark 25 mg

synthon hispania, s.l. - spania - lenalidomidum - caps. - 25mg - imunosupresoare alte imunosupresoare

LENALIDOMIDA GLENMARK 5 mg Romunija - romunščina - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

lenalidomida glenmark 5 mg

synthon hispania, s.l. - spania - lenalidomidum - caps. - 5mg - imunosupresoare alte imunosupresoare

LENALIDOMIDA GRINDEKS 10 mg Romunija - romunščina - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

lenalidomida grindeks 10 mg

as grindeks - letonia - lenalidomidum - caps. - 10mg - imunosupresoare alte imunosupresoare

LENALIDOMIDA GRINDEKS 15 mg Romunija - romunščina - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

lenalidomida grindeks 15 mg

as grindeks - letonia - lenalidomidum - caps. - 15mg - imunosupresoare alte imunosupresoare

LENALIDOMIDA GRINDEKS 2,5 mg Romunija - romunščina - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

lenalidomida grindeks 2,5 mg

as grindeks - letonia - lenalidomidum - caps. - 2,5mg - imunosupresoare alte imunosupresoare

LENALIDOMIDA GRINDEKS 20 mg Romunija - romunščina - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

lenalidomida grindeks 20 mg

as grindeks - letonia - lenalidomidum - caps. - 20mg - imunosupresoare alte imunosupresoare